GM1 Gangliosidosis: Mechanisms and Management
The Application of Clinical Genetics, 2021 Allisandra K Rha,1 Anne S Maguire,1,2 Douglas R Martin1,2 1Scott-Ritchey Research Center, Auburn University, Auburn, AL, 36849, USA; 2Department of Anatomy, Physiology, and Pharmacology, Auburn University College of Veterinary Medicine, Auburn, AL, 36849,
Anne S Maguire, Douglas R Martin
exaly +7 more sources
Sialidase NEU3 action on GM1 ganglioside is neuroprotective in GM1 gangliosidosis
Journal of Lipid Research, 2023 GM1 gangliosidosis is a neurodegenerative disorder caused by mutations in the GLB1 gene, which encodes lysosomal β-galactosidase. The enzyme deficiency blocks GM1 ganglioside catabolism, leading to accumulation of GM1 ganglioside and asialo-GM1 ...
Maria L. Allende +10 more
doaj +3 more sources
Burden of caregiving of individuals with GM1 and GM2 gangliosidoses in the United States: a qualitative study [PDF]
Orphanet Journal of Rare DiseasesBackground GM1 and GM2 (Tay–Sachs and Sandhoff diseases) gangliosidoses are rare, autosomal recessive, potentially life-threatening, disabling disorders characterized by progressive neurodegeneration, with no disease-modifying treatment. This qualitative
Maria Belen Rodriguez +8 more
doaj +2 more sources
Titration of serum anti-ganglioside antibodies in patients with chronic medular injury previous to treatment with GM1 ganglioside [PDF]
Acta Ortopédica Brasileira, 2003 Anti-ganglioside serum titers were evaluated by ELISA in 150 patients with complete spinal cord lesion for 6 to 12 months (IgG monosialo GM1, IgM monosialo GM1, IgG asialo GM1, IgM asialo GM1, IgG disialo GD1b e IgM disialo GD1b) prior to treatment with ...
Tarcísio Eloy Pessoa Barros Filho +1 more
doaj +1 more source
GM1 Oligosaccharide Efficacy in Parkinson’s Disease: Protection against MPTP
Biomedicines, 2023 Past evidence has shown that the exogenous administration of GM1 ganglioside slowed neuronal death in preclinical models of Parkinson’s disease, a neurodegenerative disorder characterized by the progressive loss of dopamine-producing neurons: however ...
Maria Fazzari +13 more
doaj +1 more source
Quantifying Lipid Contents in Enveloped Virus Particles with Plasmonic Nanoparticles [PDF]
, 2014 Phosphatidylserine (PS) and monosialotetrahexosylganglioside (GM1) are examples of two host-derived lipids in the membrane of enveloped virus particles that are known to contribute to virus attachment, uptake, and ultimately dissemination. A quantitative
Aaron +72 more
core +5 more sources
Intraventricular Sialidase Administration Enhances GM1 Ganglioside Expression and Is Partially Neuroprotective in a Mouse Model of Parkinson's Disease. [PDF]
PLoS ONE, 2015 Preclinical and clinical studies have previously shown that systemic administration of GM1 ganglioside has neuroprotective and neurorestorative properties in Parkinson's disease (PD) models and in PD patients. However, the clinical development of GM1 for
Jay S Schneider +3 more
doaj +1 more source
LDL-conjugated to GM1 micelles incorporating anticancer drugs to improve tumor cell uptake [PDF]
Nanomedicine Journal, 2021 Objective(s): The role of lipoproteins (LDL) as active molecules with preferential tumor interaction, but limited drug delivery capacity, has been previously reported.
Ariel Gustavo Garro +4 more
doaj +1 more source
Binding Cooperativity Matters: A GM1-Like Ganglioside-Cholera Toxin B Subunit Binding Study Using a Nanocube-Based Lipid Bilayer Array. [PDF]
PLoS ONE, 2016 Protein-glycan recognition is often mediated by multivalent binding. These multivalent bindings can be further complicated by cooperative interactions between glycans and individual glycan binding subunits.
Nolan C Worstell +3 more
doaj +1 more source
Advanced Science, 2023 A hallmark of Alzheimer's disease (AD) is the senile plaque, which contains β‐amyloid peptides (Aβ). Ganglioside GM1 is the most common brain ganglioside. However, the mechanism of GM1 in modulating Aβ processing is rarely known.
Xiaotong Wang +9 more
doaj +1 more source